Mexiletine in Sporadic Amyotrophic Lateral Sclerosis
Status:
Completed
Trial end date:
2018-09-30
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out whether the drug mexiletine will be
effective in lowering motor neuron electrical activity in the brains and nerves in the arms
of people with ALS. The investigators will also determine if there are any signs that the
drug may slow down the progression of ALS and reduce muscle cramps and muscle twitching. This
will be determined through transcranial magnetic stimulation (TMS) and threshold tracking
nerve conduction studies (TTNCS). In this trial, the participants will be taking either
300mg/day of mexiletine, 600mg/day of mexiletine, or placebo (non-active study drug).